王磊
Lv2
150 积分
2023-01-29 加入
-
Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
13天前
已关闭
-
Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report
27天前
已完结
-
Abstract 6754: Clinical characteristics, real-world treatment patterns, and clinical outcomes among patients with previously treated metastatic or unresectable EGFR-mutated non-small cell lung cancer in the United States
1个月前
已关闭
-
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
1个月前
已完结
-
PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC
1个月前
已完结
-
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
1个月前
已完结
-
Abstract 6754: Clinical characteristics, real-world treatment patterns, and clinical outcomes among patients with previously treated metastatic or unresectable EGFR-mutated non-small cell lung cancer in the United States
1个月前
已关闭
-
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
3个月前
已完结
-
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
4个月前
已完结
-
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
4个月前
已完结